Christelle Perros-Huguet, Ph.D., is Chief Scientific Officer for Inflammation and Remodeling in BioTherapeutics Research & Development. Her team discovers and develops targeted therapies for chronic inflammatory diseases, with a particular focus on diseases of the lungs, kidneys, and skin. The Inflammation and Remodeling team partners extensively with complementary external organizations to understand the relationship between innate immunity, tissue inflammation, and post-inflammatory remodeling to advance promising differentiated new medicines.
“It takes many different skills to develop a winning drug such as deep biology, pharmacology and drug discovery expertise. We’ve established a model with strong internal talent in key diseases and an extensive network of collaborators and external experts to better understand how danger signals and injury are sensed and integrated by the body”
Vice President, Chief Scientific Officer, Inflammation & Remodeling Research Unit
Christelle Perros-Huguet, Ph.D., is the Vice President and Chief Scientific Officer of the Inflammation & Remodeling Research Unit at Pfizer, which focuses on developing medicines for chronic inflammatory diseases, with an emphasis on chronic pulmonary diseases and chronic kidney diseases. Her research unit investigates the interplay of innate immunity, tissue inflammation and the fibrosis/remodeling processes in the initiation, maintenance and progression of chronic inflammatory conditions.
Prior to her current role, Dr. Perros-Huguet served in a number of leadership positions within Pfizer, including Chief Scientific Officer of Worldwide Pharmacokinetics Dynamics & Metabolism. Before that, Dr. Perros-Huguet was the Research Head of the Genito Urinary Therapeutic Area, leading the research strategy covering sexual health, endometriosis, overactive bladder, incontinence, interstitial cystitis and chronic kidney diseases.
Previously, while working for Pfizer in Sandwich, U.K., Dr. Perros-Huguet developed and built the site’s allergy and respiratory biology capabilities, bringing forward novel targets and exploring new mechanisms. There, she served as the Allergy & Respiratory Biology Lin Director, where she directed and led the delivery of nine novel compounds. These projects evaluated targets for chronic obstructive pulmonary disease (COPD), asthma, and allergic rhinitis, and included both small molecule and antibody modalities administered by oral, inhaled or injectable routes.
Dr. Perros-Huguet studied in France, Germany and Switzerland, receiving a French University Diplomas in Technology (DUT) in applied biology and biochemistry, and a European engineering degree in biotechnology sciences. She received a Ph.D. in molecular and cellular biology from the Institute Pasteur in France.